ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

NIH Plans Conference On DCIS Diagnosis, Management

July 17, 2009

In Brief: Walter Lawrence, Reginald Ho Lead ACS; Henderson To Leave Dana-Farber for UCSF

November 22, 1991

GYN Group: Open Surgery Would Cost More Lives Than Morcellation

July 25, 2014

ACS Expresses Concern About “Fletcher Report” On Mammography

May 7, 1993

Senate Markup Of Labor-HSS-Education Money Bill Delayed Until After Congress August Recess

August 4, 1989

In Brief: Olden Chosen To Head NIEHS; Cancer Panel To Discuss Cancer and Poverty On July 9

June 28, 1991